Hey all, welcome back to the Real Life Pharmacology podcast. I'm your host, pharmacist, Eric Christensen.

Thanks so much for listening. A couple housekeeping items I wanted to mention. Don't forget,

if you enjoy the podcast, we'd like to follow it when we've got updates, new episodes. Definitely

track us down at real life pharmacology.com. Subscribe there. If you do so,

you also get a free 31-page PDF emailed to you with the top 200 drugs and important

clinical pearls that go along with those medications. So if you're a student, you know, young health care

professional, definitely a no-brainer to go check that resource out. If you enjoy the podcast

today, definitely leave a rating review on iTunes. That's greatly appreciated. And I think we're

going to get into it. So the drug I wanted to talk about today is oral semaglutide.

So semaglutide, it's a glp1 agonist, and there is an injectable formulation.

But new to the game, within the last six to 12 12 months here there has been an oral agent,

which is the first in class. So this is a new opportunity for patients to have another

alternative in managing treating diabetes. So the brand name of oral semagglutide is ribelsis. I have to remember the

injectable formulation is ozempic. Again, GOP1 agonist. So this, from a mechanism of action standpoint,

acts as incritin, essentially in the body. And incritin is an important hormone that

plays a role in glucose management, basically. So it increases glucose-dependent insulin release. So

if you think about eating a meal, and once we eat a meal, we get that insulin release

to help bring those blood sugars down, that type of thing, that's going to help oral

semaglutide or semaglutides, going to help manage that.

So with that glucose-dependent insulin release, those are those post-pranile

after-meal sugars. I think that's a good thing to remember. So if you've got a patient that's

really struggling with those blood sugars right after meals compared to, you know, maybe those fasting levels are really high.

...